Monitor for any shareholder dissent on the authorized share increase or compensation votes. The increase in authorized shares could be used for future financing or acquisitions, but no immediate plans disclosed. Trading volume and price action around the June 10 meeting may reflect sentiment on the proposals.
Price Chart
Executive Summary
Iovance Biotherapeutics filed additional definitive proxy materials for its 2026 Annual Meeting, with proposals including director elections, say-on-pay, auditor ratification, an ESPP share increase, and a 30% increase in authorized common stock from 500M to 650M shares. The board recommends 'For' on all items. The filing is routine with no activist or dissident involvement.
Key Facts
- Annual Meeting scheduled for June 10, 2026, voting deadline June 9, 2026
- Proposal 1: Election of six directors (Iain Dukes, Athena Countouriotis, Ryan Maynard, Wayne P. Rothbaum, Frederick G. Vogt, Michael Weiser)
- Proposal 5: Increase ESPP shares by 1,000,000
- Proposal 6: Increase authorized common stock from 500M to 650M shares (30% increase)
- Board recommends 'For' on all proposals
- No activist or dissident solicitation; management filed the proxy
Financial Impact
Authorized share increase of 150M shares, potential for future dilution; ESPP increase of 1M shares is minor
Risk Factors
- Potential dilution from authorized share increase if fully issued
- Possible negative vote on say-on-pay or director elections could signal governance concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-050467 |
| Document: 0001104659-26-050467-index-headers.html | 0001104659-26-050467 |
| Document: 0001104659-26-050467-index.html | 0001104659-26-050467 |
| Document: 0001104659-26-050467.txt | 0001104659-26-050467 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $8.06 $10.64 | ▲ +32.01% | ▲ +30.70% | $14.24 (+76.67%) |
Aug 6, 2026 8w ago | 8-K | $6.34 $8.79 | ▲ +38.64% | ▲ +39.04% | $14.24 (+124.61%) |
Aug 6, 2026 8w ago | 8-K | $6.21 $8.70 | ▲ +40.10% | ▲ +39.50% | $14.24 (+129.31%) |
Jul 16, 2026 11w ago | Court Ruling | $4.66 $6.52 | ▼ −39.91% | ▼ −36.30% | $14.24 (−205.58%) |
Jul 2, 2026 13w ago | 8-K | $4.31 $4.69 | ▲ +8.82% | ▲ +9.23% | $14.24 (+230.39%) |
Jun 19, 2026 14w ago | Press Release | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.24 (+250.74%) |
Jun 18, 2026 15w ago | S-3ASR | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.24 (+250.74%) |
Jun 10, 2026 16w ago | 8-K | $3.96 $4.37 | ▲ +10.35% | ▲ +8.46% | $14.24 (+259.60%) |
May 22, 2026 18w ago | Press Release | $4.10 $4.34 | ▲ +5.87% | ▲ +7.81% | $14.24 (+247.32%) |
Apr 28, 2026 22w ago | DEFA14A | $3.31 $4.30 | ▲ +29.91% | ▲ +23.86% | $14.24 (+330.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access